Amersham and Bristol-Myers Squibb form cross-licensing deal:
This article was originally published in Clinica
Amersham Health and Bristol-Myers Squibb Medical Imaging (BMS-MI) are to cross license their ultrasound contrast agent patent rights as part of a set of deals. Neither company will pay licensing fees or royalties. The two companies will also drop all patent infringement litigation that began when BMS-MI was part of the DuPont Pharmaceuticals company. In addition, BMS-MI will distribute Amersham's nuclear medicine products in Puerto Rico. There will also be a cross licensing provision between the two companies covering radiopharmaceuticals related to angiogenesis.